research Clascoterone: First Approval
Clascoterone cream was approved in the USA for treating acne in people aged 12 and older.
Search
for
Sort by
Research
30 / 1000+ resultsresearch Androgen Receptor Inhibitors in the Treatment of Acne Vulgaris: Efficacy and Safety Profiles of Clascoterone 1% Cream
Clascoterone 1% cream is a promising new treatment for acne.
research Androgens and acne: perspectives on clascoterone, the first topical androgen receptor antagonist
Clascoterone is a new, effective, and safe acne treatment without systemic side effects.
research Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments
Spironolactone is effective for treating female hair loss, with new treatments like clascoterone showing promise.
research TRADITIONAL AND ALTERNATIVE METHODS OF ACNE TREATMENT
Spironolactone and clascoterone are promising acne treatments with fewer side effects.
research Editorial Note on Next-Generation Therapies and Advance Acne Treatment
New acne treatments like clascoterone and minocycline foam are effective, and using antibiotics carefully is important to avoid resistance.
research Clascoterone Cream 1% in Acne Management: Case Series and Real-World Canadian Experience
Clascoterone cream 1% is effective and well-tolerated for treating acne and other related conditions.
research Industry update: the latest developments in the field of therapeutic delivery, July 2018
New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.
research Real-World Experience of Clascoterone Cream 1% in Acne Management: Case Series and Canadian Experience
Clascoterone cream effectively reduces acne severity and is safe for patients 12 and older.
research Hormonal Therapies for Acne: A Comprehensive Update for Dermatologists
Hormonal therapies effectively treat acne and improve quality of life.
research Exploring Acne Treatments: From Pathophysiological Mechanisms to Emerging Therapies
Personalized acne treatments and new therapies show promise for better results.
research Topical Antiandrogen Therapies for Androgenetic Alopecia and Acne Vulgaris
Topical therapies show promise for hair loss and acne treatment with minimal side effects.
research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique
De nouvelles thérapies promettent de mieux traiter la perte de cheveux due à l'alopécie androgénétique.
research Safety of Alopecia Treatments in Patients with Breast Cancer and High-Risk Women: A Review
Alopecia treatments like 5α-reductase inhibitors and spironolactone are safe for breast cancer patients and high-risk women.
research Managing Common Dermatologic Needs in Transgender and Gender-Diverse Adolescents
Transgender and gender-diverse teens need specialized skin and mental health care.
research Recent Advances in Drug Development for Hair Loss
New treatments for hair loss show promise with advanced therapies and better targeting.
research Clascoterone: a new topical antiandrogen agent.
Clascoterone is a promising topical treatment for hair loss and acne with fewer side effects.
research Expanding the therapeutic versatility of clacosterone
Clascoterone cream could be used for other skin conditions affected by hormones.
research Clascoterone as a novel treatment for androgenetic alopecia
Clascoterone may be a promising treatment for hair loss.
research A Phase 1 Study to Investigate the Effects of Cortexolone 17α‐Propionate, Also Known as Clascoterone, on the QT Interval Using the Meal Effect to Demonstrate ECG Assay Sensitivity
Clascoterone is safe for the heart, even at high doses.
research Cortexolone 17α-Propionate (Clascoterone) is an Androgen Receptor Antagonist in Dermal Papilla Cells In Vitro
Clascoterone may be an effective topical treatment for hair loss.
research A summary of in vitro, phase I, and phase II studies evaluating the mechanism of action, safety, and efficacy of clascoterone (cortexolone 17a propionate, CB-03-01) in androgenetic alopecia
Clascoterone safely promotes hair growth similar to minoxidil.
research Lenalidomide for refractory cutaneous manifestations of pediatric systemic lupus erythematosus
Lenalidomide effectively and safely treats skin symptoms in pediatric lupus, reducing the need for prednisone.
research Wedelolactone: A Natural Anti-inflammatory Coumarin Derivative
Wedelolactone may help treat chronic diseases due to its strong antioxidant properties.
research 565 Cutaneous delivery of LEKTI via an engineered strain of staphylococcus epidermidis for the treatment of netherton syndrome
ATR12-351 ointment safely delivers LEKTI protein to the skin, reducing enzyme activity in Netherton syndrome.
research CUTANEOUS T-CELL LYMPHOMA
The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.
research Clobetasol/minoxidil
research Cutaneous lupus erythematosus induced by tislelizumab
Tislelizumab can cause cutaneous lupus erythematosus.
research Characteristics and Alternative Treatment Outcomes of Antimalarial-Refractory Cutaneous Lupus Erythematosus
Thalidomide works best for skin lupus not helped by antimalarials, but has many side effects; other treatments are less effective, especially if patients also have systemic lupus.
research Equivalent chemotherapy efficacy against leukemia in mice treated with topical vasoconstrictors to prevent cancer therapy side effects
Topical vasoconstrictors do not reduce chemotherapy effectiveness against leukemia in mice.